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INTRODUCTION
Non-infectious granulomatous lung disease represents 
a diverse group of disorders characterized by pulmonary 
opacities associated with granulomatous inflammation, 
a relatively nonspecific finding commonly encountered 
by pathologists [1-3]. Granuloma formation is a chronic 
inflammatory reaction involving the macrophage system 
and other inflammatory cells. In affected organs, the 
first manifestation of granuloma is an accumulation 
of mononuclear inflammatory cells, mostly T cells and 
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monocyte macrophages [4,5]. The early inflammatory 
process is followed by the organization of the granuloma, 
a compact and highly dynamic structure composed of a 
central cluster of mononuclear phagocytes and epithelioid 
multinucleated cells, generally surrounded by a rim of 
lymphocytes [6-9].
Patients with non-infectious pulmonary granulomatosis 
may initially be identified based on pulmonary symptoms 
or chest radiographic abnormalities [10-12]. A large 
variety of non-infectious pulmonary disorders may be 
associated with occasional granulomatous lesions: 
1) inflammatory: sarcoidosis and necrotizing sarcoid 
granulomatosis (NSG); 2) pulmonary lymphoid lesions: 
lymphomatoid granulomatosis (LYG); granulomatous-
lymphocytic interstitial lung disease (GLILD); 3) aspiration/
exposure: aspiration pneumonia, talcosis, berylliosis, 
and hypersensitivity pneumonitis (HP); 4) vasculitis: 
granulomatosis with polyangiitis (GPA) (formerly Wegener's 
granulomatosis) and eosinophilic granulomatosis with 
polyangiitis (EGPA) (formerly Churg-Strauss syndrome); and 
5) collagen vascular disorders: rheumatoid lung nodules.
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Diverse and nonspecific findings may be seen on 
conventional chest radiography. High-resolution computed 
tomography (HRCT) demonstrates more characteristic 
patterns and distribution of parenchymal opacities than 
chest radiography. Although CT findings are often helpful, 
there is still a considerable overlap of imaging findings 
among the various forms of non-infectious pulmonary 
granulomatosis [13,14].
Herein, we describe and illustrate the imaging features of 
common and uncommon non-infectious granulomatous lung 
disease and correlate these features with the pathologic 
findings in order to suggest a specific diagnosis or to 
substantially narrow the differential diagnosis using the 
imaging appearance and anatomic location of the lesion.
Pulmonary Inflammatory Lesions 
Sarcoidosis
Sarcoidosis is a multisystem granulomatous disorder of 
unknown origin with worldwide distribution and protean 
clinical manifestations. It is a global disease with a 
worldwide incidence of 1–40 cases per 100000 people per 
year and a prevalence of 0.2–64 cases per 100000 people 
[15-18]. The disease mainly affects people in the third and 
fourth decades of life but may also occur in children and 
elderly subjects. It is characterized by a T-helper response 
in which CD4 lymphocytes and activated macrophages 
accumulate in affected organs, resulting in granuloma 
formation.
Pulmonary involvement is the most common feature, 
occurring in more than 95% of patients with bilateral 
hilar lymphadenopathy; multiple organ systems may also 
be involved [18]. Approximately 30% to 50% of patients 
are asymptomatic, with bilateral hilar lymphadenopathy 
detected incidentally on chest radiography. The most 
common pulmonary complaints are cough, shortness 
of breath, dyspnea, and bronchial hyperreactivity; 
constitutional symptoms are common and include fever, 
fatigue, weakness, malaise, and weight loss [15,16,19]. 
Although in the majority of patients, pulmonary sarcoidosis 
follows a benign course and tends to resolve spontaneously, 
in a significant minority, granulomas evolve to progressive 
fibrosis. Löfgren’s syndrome is a clinically distinct 
phenotype of sarcoidosis; patients typically experience an 
acute disease onset usually with fever, and characteristic 
symptoms of bilateral hilar lymphadenopathy, erythema 
nodosum, and/or bilateral ankle arthritis or periarticular 
inflammation [20,21]. Immune checkpoint blockade has 
been associated with multiple distinctive side effects 
termed as immune-related adverse events. The most 
common pulmonary toxicities of these agents include 
pneumonitis and sarcoid-like granulomatosis that may be 
detected during follow-up imaging studies, such as CT or 
PET/CT [22]. 
The diagnosis of sarcoidosis is confirmed when typical 
clinical and radiological findings are supported by 
histological evidence of non-necrotizing granulomas and 
exclusion of possible alternative diagnoses [23-26]. 
The classic histologic findings in sarcoidosis are well-
formed, compact, non-necrotizing granulomas often 
surrounded by concentric layers of hyaline collagen, 
confined to the interstitial compartment, and distributed 
in a characteristic lymphangitic pattern [23,27-29]. Sarcoid 
granulomas are always well-circumscribed interstitial groups 
of epithelioid histiocytes, multinucleated giant cells, 
and variable numbers of chronic inflammatory cells. This 
feature is helpful and is in contrast to the poorly formed 
granulomas seen in HP [30]. Gross findings comprise 
variably sized nodules showing a distinctive predilection for 
bronchovascular bundles, interlobular septa, and visceral 
pleura. Distribution of granulomas in a lymphangitic pattern 
is a distinctive feature of sarcoidosis that can be extremely 
helpful for diagnosis. Infectious granulomas tend to be 
randomly scattered in the parenchyma, and the granulomas 
of HP are often centrilobular. Usually, a biopsy is required 
to demonstrate non-necrotizing granulomas. However, an 
accurate distinction between different causes of granulomas 
is, in many cases, not possible.
Parenchymal disease results from interstitial involvement 
by the granulomatous process leading to irreversible 
parenchymal changes related to fibrosis. At presentation, 
the chest radiograph is abnormal in approximately 90% of 
patients. The most characteristic radiologic findings are 
symmetric bilateral hilar and right paratracheal lymph node 
enlargement or diffuse micronodular pulmonary infiltration. 
Eggshell calcification is thought to develop only in affected 
nodes and is related to disease duration.
Several HRCT findings have been associated with 
sarcoidosis, reflecting the histologic findings; small nodules 
along the bronchovascular bundles, interlobular septa, 
major fissures, and pleural/subpleural regions represent 
the typical perilymphatic distribution (Fig. 1) [24,31,32]. 
Other HRCT signs of sarcoidosis are the reversed halo sign, 




approximately complete ring of consolidation (Fig. 2) and 
the galaxy sign, a lung nodule formed by the confluence 
of multiple small-sized nodules which separate from one 
another (Fig. 3). Confluence of granulomas may also 
result in nodules or masses measuring 1–4 cm in diameter. 
Fibrotic conglomerate masses, reminiscent of those seen 
in silicosis, may also develop in advanced disease. These 
findings typically predominate in the middle and upper lung 
zones [33]. If less characteristic clinical or radiological 
manifestations predominate, fluorodeoxyglucose (FDG)-
FDG-PET, which is highly sensitive in detecting active 
granulomatous lesions, can be used [34].
Progressive fibrosis and architectural distortion lead 
to honeycombing, fibrocystic changes, bullae, traction 
bronchiectasis, and retraction of the pulmonary hila. Air 
trapping because of small airway obstruction may also be 
observed [35]. Superimposed infection of fibrocystic spaces, 
particularly with Aspergillus, is a frequent complication 
of sarcoidosis and accounts for significant morbidity and 
mortality [36-38].
Necrotizing Sarcoid Granulomatosis
NSG is a form of granulomatous lung disease first 
described in 1973 by Liebow [39] and is characterized by 
extensive vascular granulomas that infiltrate and occlude 
pulmonary arteries and veins, accompanied by widespread 
necrosis of lung tissue. Initially, NSG was considered as 
a provisional diagnostic term; however, the problem was 
whether the disease represented necrotizing angiitis 
with sarcoid reaction or sarcoidosis with necrosis of the 
Fig. 1. Sarcoidosis in 51-year-old male (perilymphatic pattern). 
A. Close-up view of an axial CT scan shows sparse micronodules with a typical perilymphatic distribution, especially along the fissures (arrowheads) 
and bronchovascular bundles (arrows). B. Low-power scanning magnification demonstrates the lymphangitic distribution of granulomas involving 
bronchovascular bundles, pleura, and interlobular septa typical of sarcoid (arrows). These findings correlate with the CT appearance (hematoxylin 
and eosin stain, X 40).
A B
Fig. 2. Sarcoidosis in 28-year-old female (reversed halo sign). 
A. Close-up view of a coronal CT scan shows two central ground-glass opacities surrounded by a more or less complete ring of consolidation 
(reversed halo sign) (arrow). B. Medium power magnification demonstrates the compact, well-circumscribed non-necrotizing granulomas 
containing multinucleated giant cells typical of sarcoid (arrow) (hematoxylin and eosin stain, X 200).
A B
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granulomas and the vessels [40-43]. Granulomatous 
pulmonary angiitis is a nonspecific lesion observed in a 
variety of conditions, including Wegener’s granulomatosis, 
NSG, chronic beryllium disease (CBD), foreign body 
embolization in drug abusers, and schistosomiasis [44]. 
NSG no longer qualifies as a separate entity [42]. The term 
“sarcoidosis with NSG pattern” should be used in place of 
NSG to reflect the clinical entity of nodular sarcoidosis [45].
Although the clinical presentation is variable, the 
majority of patients present with respiratory and systemic 
symptoms and nodular lung lesions simulating metastatic or 
primary lung neoplasms. Cough is the most common clinical 
manifestation, followed by chest pain, dyspnea, fever, and 
constitutional symptoms of weight loss and fatigue. Patients 
with NSG have no upper airway disease, glomerulonephritis, 
or systemic vasculitis; extrapulmonary involvement has 
been observed in 20% to 30% of cases [46,47].
The histopathologic features of pulmonary NSG show 
sarcoid-like granulomas with central necrosis and 
granulomatous vasculitis [44,46,48].
The predominant radiologic findings were multiple round 
or oval pulmonary nodules without a specific relationship 
to lobular structures and interlobular septa. A uniform or 
random distribution throughout the lungs and a relationship 
with pleural surfaces and fissures are common. The nodule 
margin is most often well defined. Cavitation may be seen 
on follow-up CT images [49].
Multiple large nodular lesions, seen in 1.5% to 4% 
of patients, are a rare manifestation of pulmonary 
sarcoidosis (Fig. 4) [50].
Fig. 3. Sarcoidosis in 40-year-old male (galaxy sign).
A, B. Axial (A) and coronal (B) CT images show multiple upper lobe–predominant solid pulmonary nodules surrounded by tiny satellite 
micronodules 1–2 mm (arrows).
A B
Fig. 4. Necrotizing sarcoid granulomatosis. 
A. Coronal (MIP reformatted image) chest CT shows bilateral nodular opacities with irregular borders (arrows). B. Coronal (minIP reformatted 
image) chest CT shows hypodense nodules (arrow). Mediastinal and hilar adenopathies are also seen (arrowheads). C. Medium-power 
magnification demonstrates a conglomeration of necrotizing (pale eosinophilic hypocellular zones) granulomas with scattered multinucleated 
giant cells (arrows) compatible with “sarcoidosis with necrotizing sarcoid granulomatosis pattern” that correlates with nodules and masses seen 





Pulmonary Lymphoid Lesions 
Lymphomatoid Granulomatosis (LYG)
LYG is a very rare Epstein-Barr virus (EBV)-driven 
lymphoproliferative disease involving extra-nodal sites and 
is composed of EBV-positive B cells admixed with reactive 
T cells, which usually predominate [51-55]. In the current 
WHO classification, LYG is grouped along with NHL as a 
neoplasm of mature B cells [56]. Histologically, LYG shows 
an angiocentric and angiodestructive accumulation of 
heterogeneous polymorphous group of T cells with varying 
numbers of atypical clonal EBV-positive B cells around the 
muscular arteries and veins, with the invasion of these 
vessels and areas of necrosis presenting later in the disease 
process [51,57].
Pulmonary involvement occurs in > 90% of patients and 
is usually present at initial diagnosis. The clinical behavior 
of LYG varies widely; the disease ranges from an indolent 
process, which may result in spontaneous remission, 
to an aggressive large B-cell lymphoma. Predisposing 
conditions include patients with an underlying acquired or 
inherited immunodeficiency syndrome (e.g., Wiskott Aldrich 
syndrome, X-linked lymphoproliferative syndrome, HIV/
AIDS, allogeneic organ transplantation) or autoimmune 
diseases (e.g., Sjögren syndrome, rheumatoid arthritis, 
sarcoidosis, ulcerative colitis, and common variable 
immunodeficiency). LYG can lead to progressive pulmonary 
failure, central nervous system disease, or progression to 
overt EBV-positive lymphoma.
The most common radiologic and CT features observed in 
approximately 80% of all cases are unilateral or bilateral 
multiple lung nodules 0.5–8 cm in diameter with a 
peribronchovascular distribution and basal predominance 
(Fig. 5) [58]. The lesions can progress rapidly, coalesce, 
and cavitate (Fig. 6). Nodules can disappear or migrate 
spontaneously, and a “reversed halo sign” is frequently 
observed [59,60]. Mediastinal lymph node enlargement 
is rare. Pleural effusion is sometimes present. FDG PET-CT 
shows avid FDG uptake in these lesions [61].
Common Variable Immunodeficiency (CVID)/
Granulomatous-Lymphocytic Interstitial Lung Disease 
(GLILD)
Common variable immunodeficiency is a primary 
immunodeficiency of unknown etiology that leads to a 
clinical syndrome with low levels of serum immunoglobulins 
and an inability to make specific antibodies [62,63]. CVID is 
characterized by recurrent bacterial infections, particularly 
in the respiratory tract, and due to defects in cellular 
immunity, CVID may also predispose to opportunistic 
infections [64,65]. Secondary causes of decreased serum 
immunoglobulin levels must be ruled out in any patient 
that meets the diagnostic criteria for CVID [66]. A CT 
scan at the time of diagnosis can identify bronchiectasis, 
interstitial lung disease, and granulomatous lung disease, 
even in asymptomatic patients. Follow-up chest CT should 
Fig. 5. Lymphomatoid granulomatosis a 56-year-old female.
A. Axial pre-contrast CT image demonstrates multiple pulmonary nodules and masses (arrows). Nodules and masses are distributed along 
bronchovascular bundle and in subpleural region. Large mass in the right lower lobe is cavitary (arrowhead). B. Autopsy gross specimen shows 
multiple ill-defined yellowish nodules (black arrows) that coalesce leading to large masses (white arrows). C. High-power magnification 
demonstrates vessel wall destruction by marked infiltrates of small Tlymphocytes that obscure malignant large B-lymphocytes seen in 
lymphomatoid granulomatosis (arrows) (hematoxylin and eosin stain, X 400).
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be used judiciously because of the malignancy risk [66,67].
Approximately 10–30% of patients with CVI develop 
clinical evidence of a non-infectious multisystemic 
lymphoproliferative disease, which includes diffuse 
adenopathy, splenomegaly, and granulomatous 
inflammation in a variety of organs. While airway diseases 
include infection, obstructive disease, and bronchiectasis, 
interstitial lung diseases include granuloma, organizing 
pneumonia, and lymphoid infiltrative disease [66]. 
Pathologically, it is characterized by both granulomatous 
and lymphoproliferative histologic patterns [68]. Imaging 
findings consist of bronchiectasis (cylindrical, varicoid, or 
cystic), mucoid impaction, and airway thickening [69-72]. 
The presence of bronchiectasis has been correlated with 
abnormal CD4+ T cell levels [73].
The term GLILD has been used to describe lymphoid 
parenchymal proliferation that usually consists of 
noncaseating granulomas, lymphocytic interstitial 
pneumonia, peribronchiolar lymphoid proliferation (follicular 
bronchiolitis), and lymphoid hyperplasia [74]. Organizing 
pneumonia has also been sometimes considered a part of 
GLILD [62,75]. Typical CT imaging findings include solid 
nodules (< 3 cm), semisolid nodules, pure ground-glass 
opacities, enlarged thoracic (hilar and/or mediastinal) 
lymph nodes, and splenomegaly (Fig. 7) [76].
Fig. 6. Lymphomatoid granulomatosis a 62-year-old male. 
A. Posteroanterior chest imaging shows a large cavitary mass in the left upper lobe (arrows). Ill-defined randomly distributed rounded opacities 
are iobserved in the rest of the lung parenchyma (arrowheads). B. Corresponding axial chest CT scan shows multiple rounded peripheral solid (black 
arrows) or cavitary nodules (white arrows).
A B
Fig. 7. Granulomatous-lymphocytic interstitial lung disease. 
A. Axial chest CT scan shows multiple peripheral and peribronchovascular ground-glass and consolidation (arrows). B. Low-power scanning 
magnification of lung demonstrates airway centered marked infiltrates of chronic inflammatory cells (black arrows) that results in cystic 
remodeling of distal small airways (white arrows) (hematoxylin and eosin stain, X 40). C. High-power magnification demonstrates poorly formed 
collection of histiocytes and a multinucleated giant cell (arrows). The airway centered lung injury correlates with the peribronchovascular ground 






The term aspiration describes a variety of situations 
involving the intake of solid or liquid materials into the 
airways and lungs [77,78]. Aspiration may occur from 
exogenous or endogenous gastric sources. The development 
of aspiration-related pulmonary syndrome depends on the 
quantity and nature of the aspirated material, chronicity, 
and host responses [79]. Alcoholism is probably the most 
important predisposing factor for pulmonary aspiration in 
adults, although other factors (e.g., general anesthesia, loss 
of consciousness, structural abnormalities of the pharynx 
and esophagus, neuromuscular disorders, and deglutition 
abnormalities) may also contribute to aspiration [78,80-82].
Aspiration Pneumonia 
Pulmonary aspiration of gastric contents is a significant 
cause of morbidity and mortality and is the most common 
cause of pneumonia [77,81]. Predisposing factors, such 
as neurologic disorders, structural abnormalities of the 
pharynx and esophagus, emergency surgical procedures, 
and dementia are frequently associated with this condition 
[77]. The most common radiographic pattern is that of 
bronchopneumonia with scattered air-space opacities. CT 
has been regarded as the imaging modality of choice for the 
evaluation of suspected esophagopleural fistula, because 
the site of communication between the pleural space 
and the esophagus can often be seen (Fig. 8). Aspiration 
of leguminous vegetables can cause a granulomatous 
pneumonitis know as lentil aspiration pneumonia. Typically 
manifesting as diffuse, ill-defined, small 1–3 mm nodular 
areas of increased opacity representing the bronchiolar 
distribution of the aspirated material [83]. On HRCT, lentil 
aspiration pneumonia manifests as centrilobular nodules, 
some with a tree-in-bud appearance [81]. Material from 
repeated aspirations may appear as disseminated miliary 
nodules representing inflammation with foreign body 
reaction in bronchioles, ducts, and alveolar sacs [77,83].
Histologically, aspiration pneumonia is classically 
characterized by acute inflammation and necrosis centered 
on bronchioles with remnants of aspirated vegetable 
material surrounded by multinucleated giant cells [83,84]. 
Talcosis 
Talc (hydrous magnesium silicate) is a mineral widely 
used in the ceramic, paper, plastics, rubber, paint, and 
cosmetic industries. The term “talc” is used not only for 
pure magnesium silicate but also for a mixture of minerals 
with various other products [85,86].
Pulmonary talcosis should be suspected in patients with 
a known history of occupational exposure or drug addiction. 
The causes of pulmonary talcosis may include inhalation 
of pure talc, inhalation of talc in association with silica 
(talcosilicosis), or inhalation of talc in association with 
asbestos fibers (talcoasbestosis). Intravenous injection 
of talc (intravascular talcosis) occurs most often during 
recreational drug use when the drug is crushed, melted, 
dissolved in water, and IV-injected. 
History of occupational exposure or drug addiction is 
the major clue to diagnosis [87-91]. Clinically, patients 
with pulmonary talcosis can range from asymptomatic 
to severe disease [92]. A wide variety of pulmonary 
complications, including asthma exacerbation, barotrauma, 
hilar lymphadenopathies, and bullous emphysema, may be 
Fig. 8. Aspiration pneumonia in 72-year-old male smoker.
A. Coronal reformatted contrast-enhanced CT shows right upper lobe heterogeneous consolidation and a large empyema (arrows). B. Medium-
power magnification of lung shows airway centered fibrosis containing two clusters of multinucleated giant cells (arrows) (hematoxylin and eosin 
stain, X 40). C. On high-power magnificent in the right histologic image, the multinucleated giant cells and organizing pneumonia surround 
fragments of plant material (arrows) (hematoxylin and eosin stain, X 400).
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associated with the inhalation of talc, silica, and lactose [93]. 
The majority of patients usually present with nonspecific 
complaints, including progressive exertional dyspnea and 
cough [93,94]. Late complications include interstitial 
pneumonitis, fibrosis, emphysema, pulmonary arterial 
hypertension, cor pulmonale, and lung cancer [95-98].
Whether inhaled or injected, talc causes non-necrotizing 
granulomatous inflammation. In the early stages of the 
disease, talcosis consists of multiple, small, foreign body 
granulomas composed of multinucleated cells containing 
birefringent crystals, which are identified in the alveolar 
septa and air spaces [11,99]. As the disease progresses, 
the granulomas can become confluent, resulting in 
heterogeneous conglomerate masses. Microscopic 
examination under polarized light shows birefringent 
needle-shaped talc crystals in multinucleated giant cells 
and macrophages. These features differ from those seen 
after intravenous talc injection where the talc particles are 
larger and become trapped within pulmonary arterioles and 
capillaries resulting in thrombosis, vascular and perivascular 
fibrosis, and chronic inflammation; intravascular and 
perivascular granulomas can be seen.
In early-stage disease, radiologic diagnosis of pulmonary 
talcosis is difficult because the findings are often minimal 
or nonspecific, consisting of extremely tiny, round opacities 
diffusely distributed throughout both lungs [100]. Earlier 
thin-section CT findings show a diffuse micronodular pattern 
with well-defined centrilobular nodules or diffuse ground-
glass opacities (Fig. 9); apices and costophrenic sulci are 
generally spared. In more advanced disease, thin-section 
CT shows progressive massive fibrosis associated with lower 
lobe emphysema and diffuse reticulonodular changes [101]. 
Although CT findings in advanced talcosis are similar to 
those reported in silicosis, conglomerate masses with areas 
of high attenuation usually involve the upper lung zones in 
silicosis, while in talcosis, they are distributed throughout 
all lung zones [11,100].
Fig. 9. Talcosis.
A, B. Axial and coronal reformatted CT images show numerous small bilateral centrilobular nodules, associated with a tree-in-bud pattern (arrows).
C. Lung tissue biopsy demonstrates an interstitial granulomatous reaction to the talc particles (arrowhead) with a giant-cell reaction (arrow) 









Beryllium is a naturally light-weight metal extracted 
from ores and processed into metal, oxides, alloys, and 
composite materials [102]. The major applications are in 
automotive electronics, telecommunications, computers, 
aerospace, ceramics, fluorescent lamps and neon lights, and 
dentistry and dental supplies [103-105].
Berylliosis, a granulomatous disorder caused by exposure 
and inhalation of dust, fumes, or aerosols of beryllium metal 
or its salts, is characterized by the accumulation of CD4+ T 
cells and macrophages in the lower respiratory tract [86].
The clinical course varies with the intensity and 
chronicity of exposure, and patients can range from 
asymptomatic to those with severe disease [106,107]. 
Symptoms usually include dyspnea, cough, fever, anorexia, 
and weight loss [108]. Pulmonary function testing shows 
restriction with diminished diffusing capacity. There are two 
distinct types of lung injury related to beryllium exposure: 
1) acute beryllium pneumonitis caused by direct acute 
lung injury resulting from the inhalation of high levels 
of beryllium particles and 2) CBD caused by delayed-type 
hypersensitivity developed months or years after exposure. 
CBD may be nearly radiographically indistinguishable from 
sarcoidosis; current workplace protection has virtually 
eliminated acute disease [109,110]. CBD continues to occur 
in the nonoccupational setting and among bystanders in 
industry, masquerading as sarcoidosis [111].
Histologically, well-formed non-necrotizing granulomas 
are seen in a lymphatic distribution involving 
bronchovascular bundles, pleura, and interlobular septa 
indistinguishable from other granulomatous disorders, such 
as sarcoidosis [112]. Confluence of numerous interstitial 
granulomas can result in large, irregular, mass-like opacities. 
Environmental exposure history may help distinguish 
between pneumoconioses and sarcoidosis [113].
In the early stage of the disease, minimal or no visible 
abnormalities may be observed on chest radiographs, 
although thin-section CT scans demonstrate thickened 
intralobular and interlobular lines [114,115].
Chest radiography is often normal in early-stage 
disease but disease progression depicts small nodules 
and reticulation, typically with predominant distribution 
in the middle and upper lung (early) [115]. Reticulation, 
architectural distortion, honeycombing, and mass-like 
lesions are observed because of the coalescence of small 
nodules and lymphadenopathy [115,116].
Characteristic CT findings include the presence of small 
nodules (< 3 mm) in a perilymphatic distribution and nodular 
thickening along the lymphatics in the bronchovascular 
sheath and, to a lesser extent, in the interlobular septa and 
subpleural lung regions (Fig. 10) [86,115]. 
Hypersensitivity Pneumonitis 
HP, one of the most common diffuse parenchymal lung 
diseases, is an immunologically mediated diffuse lung 
disease characterized by a complex immunological reaction 
of the lung parenchyma in response to repetitive inhalation 
of a sensitized allergen [117,118]. The severity of the 
disease and clinical presentation varies depending on the 
inhaled antigen and quantity. It has been conventionally 
classified into acute, subacute, and chronic forms based on 
the time course and presentation. Chronic HP is a fibrotic 
lung disease resulting from long-term exposure to an 
offending antigen [119]. 
More recently, the results of a cluster analysis were 
compared with the classical classification of HP [120]. 
Results suggest that patients with HP should be classified 
into only one of the two categories (Cluster 1 and Cluster 2) 
Fig. 10. Berylliosis in a 49-year-old male who worked for 7 years in metal polishing.
A, B. Axial thin-section CT scans (1.0-mm-thick-sections) obtained at the levels of the bronchus intermedius (A). At the basal segmental 
bronchus shows multiple small nodules along the bronchovascular bundles (straight arrows) and in subfissural regions (arrowheads) and enlarged 
hilar lymph nodes (curved arrows) (B). C. High-power magnification of a pathologic specimen obtained with mediastinoscopic lymph node biopsy 
shows multiple noncaseating granulomas (arrows) (Courtesy of Chong S) (hematoxylin and eosin stain, X 400).
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based on clinical evaluation, pulmonary function tests, and 
HRCT findings. In Cluster 1, patients would present with 
recurrent systemic symptoms (chills and body aches) and 
tightness of the chest occurring a few hours after antigen 
exposure, inspiratory crackles would be frequent, and chest 
X-rays would be normal in almost 30% of the cases. In 
Cluster 2, patients would present with features of advanced 
interstitial lung disease, clubbing, inspiratory crackles, a 
restrictive pattern on pulmonary function tests, and resting 
hypoxemia. One-third of the patients showed fibrotic 
changes on HRCT [120].
Histologic studies in acute HP are scanty, as lung biopsy 
is generally not necessary for diagnosis. The histologic 
changes of subacute HP occur at the level of the terminal 
bronchioles and consist of a classic histologic triad of a 
lymphocytic interstitial infiltrate, organizing pneumonia, 
and poorly formed non-necrotizing granulomas [121]. 
Typical granulomas are present in approximately 80% 
of surgical biopsies and consist of loose collections of 
histiocytes or scattered giant cells. Necrosis is not a 
component of the granulomatous reaction in cases of 
HP [122]. A mild perivascular lymphoid accumulation is 
typically present in HP, but prominent germinal centers 
or dense lymphoplasmacellular infiltration along vascular 
sheaths are not typical and should raise concern for 
lymphoproliferative disease [121]. Chronic HP can appear 
like usual interstitial pneumonia (UIP) on histology, but it 
is distributed in the upper lobes rather than the lower lobes 
as in UIP/IPF. The characteristic HRCT findings of acute and 
subacute HP are characterized by ground-glass attenuation 
with poorly defined centrilobular nodular opacities (Fig. 
11), thin-walled cysts, and mosaic perfusion (focal areas of 
air trapping) (Fig. 12) [123]. Coexisting thin-walled cysts 
have been reported in 13% of the patients with subacute 
HP and are believed to be caused by partial bronchiolar 
obstruction by peribronchiolar lymphocytic infiltration 
[124]. Chronic HP has a bronchovascular distribution 
Fig. 11. Subacute or cluster 1 hypersensitivity pneumonitis.
Axial thin-section CT scan at the level of lung bases shows diffuse 
ground-glass opacity interposed with areas of normal lung and lobular 
areas of decreased attenuation (arrows).
Fig. 12. Subacute or cluster 1 hypersensitivity pneumonitis.
A. Close-up view of thin-section CT scan at the level of the right-lower lobe shows diffuse ground-glass opacities and poorly defined centrilobular 
nodules (arrows). Note lobular areas of decreased attenuation and vascularity reflecting air trapping (arrows). B. Medium-power magnification 
of lung demonstrates airway centered chronic inflammation containing poorly formed granulomata (arrows). The chronic inflammatory infiltrates 






of fibrosis, reticular pattern, air trapping, and traction 
bronchiectasis (Fig. 13) [125,126]. Importantly, subacute 
and chronic HP may mimic several interstitial lung diseases, 
including nonspecific interstitial pneumonia and UIP, 
making diagnosis extremely difficult because of the overlap 
of the clinical history, and the functional and imaging 
findings [127-129]. The best diagnostic approach is to 
integrate clinical, radiological, and pathological information 
at a multidisciplinary team meeting.
Vasculitis
Granulomatosis with Polyangiitis (GPA)
GPA, formerly termed Wegener’s granulomatosis, is 
an antineutrophil cytoplasmic autoantibodies (ANCA)-
associated systemic vasculitis typically involving the upper 
respiratory tract, lower respiratory tract (bronchi and 
lungs), and kidneys, with varying degrees of disseminated 
vasculitis [39,130].
The spectrum and severity of GPA are heterogeneous, 
ranging from an indolent disease involving only one site 
to fulminant, multi-organ vasculitis leading to death 
[131]. The disease classically presents with upper and 
lower respiratory tract symptoms and renal involvement. 
Pulmonary involvement occurs in 55–90% of patients. 
Clinical pulmonary manifestations include cough, dyspnea, 
impaired pulmonary function, bronchostenosis, and diffuse 
alveolar hemorrhage [131-133].
GPA has many histopathological features. The 
microscopic hallmark is a triad of parenchymal necrosis, 
vasculitis, and granulomatous inflammation. The major 
histopathologic features of GPA are those generally 
regarded as the diagnostic criteria: parenchymal necrosis, 
vasculitis, and granulomatous inflammation accompanied 
by a mixed infiltrate of neutrophils, lymphocytes, plasma 
cells, macrophages, giant cells, and eosinophils [134]. 
Less frequent features not representing diagnostic 
criteria are alveolar hemorrhage, organizing intraluminal 
fibrosis, lymphoid aggregates, tissue eosinophils, 
xanthogranulomatous lesions, alveolar macrophage 
accumulation, and organizing pneumonia-like fibrosis 
[133,135]. The diagnosis ultimately relies on a constellation 
of radiographic and pathologic findings, laboratory values, 
and accurate clinical history [136].
GPA in the thorax presents with a wide variety of 
radiologic findings [137-140]. Chest radiographs are 
abnormal in 70% of the patients during the course of the 
disease. Lesions can be single or multiple (usually < 10 
lesions) and range in size from a few millimeters to over 
10 cm. Common pulmonary radiologic findings include 
bilateral waxing and waning nodules and masses, cavitation 
in nodules larger than 2 cm with a thick wall and irregular 
inner lining, ground-glass opacities, and consolidations 
(Fig. 14) [140]. Pleural effusion can result from primary 
involvement or secondary to renal failure. 
The characteristic CT manifestations consist of bilateral 
subpleural or peribronchovascular nodules or masses (1–4 
cm in diameter), sometimes spiculated; in approximately 
50% of the cases, the masses may cavitate [140,141]. 
Nodules with feeding vessels and wedge-shaped lesions 
abutting the pleura are less frequent findings. In unusual 
cases, the disease may manifest itself as a solitary lung 
lesion that can measure up to 10 cm in diameter [142]. 
In up to 50% of patients, bilateral nonsegmental or 
peribronchovascular areas of airspace consolidation, 
peribronchial thickening, small centrilobular nodules, and 
branching linear structures (so-called tree-in-bud pattern) 
are frequently seen [138,143]. Ground-glass opacities 
and airspace consolidation correlate with focal or diffuse 
pulmonary hemorrhage that occurs in approximately 10% of 
patients [138,140,142,144-146]. Histologically, pulmonary 
hemorrhage may result in areas of organizing pneumonia-
like reactions (Fig. 15) [147]. Calcification within areas 
of consolidation, although rare, has also been described 
[148]. Moreover, GPA associated with abnormal pulmonary 
Fig. 13. Chronic or cluster 2 hypersensitivity pneumonitis.
Typical CT findings of biopsy-proven chronic hypersensitivity 
pneumonitis in a bird breeder. High-resolution CT scans show mild 
reticulation with superimposed patchy ground-glass opacities and 
traction bronchiectasis and bronchiolectasis (white arrowheads). 
Lobular areas of decreased attenuation and vascularity (black arrows) 
are also present.
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perfusion at the subsegmental level results in ischemia 
or frank infarctions leading to ground-glass opacities 
representing necrotic cellular infiltrates in the alveoli or 
mosaic perfusion [140]. Enlarged mediastinal lymph nodes, 
always seen in association with parenchymal abnormalities, 
occur in up to 15% of cases [140]. 
Eosinophilic Granulomatosis with Polyangiitis (EGPA)
The Chapel Hill consensus conference in 1994 defined 
EGPA (formerly Churg-Strauss syndrome) as eosinophil-rich 
and granulomatous inflammation involving the respiratory 
tract and necrotizing vasculitis affecting small to medium-
sized vessels, occurring in patients with late-onset asthma 
and sustained peripheral blood eosinophilia [149].
The American College of Rheumatology criteria for 
the diagnosis of EGPA include: 1) asthma, 2) peripheral 
blood eosinophilia greater than 10% of white blood cell 
differential count, 3) neuropathy, 4) migratory or transient 
pulmonary opacities, 5) paranasal sinus abnormalities, 
and 6) tissue eosinophilia [150]. The diagnosis of EGPA 
can be established if four or more of the previous criteria 
are present. Asthma is present in almost all patients and 
usually precedes vasculitis for several years, and is often 
associated with rhinitis, nasal polyposis, or sinusitis 
[151]. ANCA are present in approximately 40% of patients. 
Symptomatic cardiac involvement occurs in as many as 
27–47% of cases and is a major contributor to disease-
related death in EGPA [152]. 
Clinically, EGPA occurs mainly in middle-aged adults 
with various degrees of eosinophilic inflammation and 
necrotizing vasculitis [153,154]. EGPA typically develops 
into three sequential phases: 1) prodromal or allergic phase, 
Fig. 14. Granulomatosis with polyangiitis in a 68-year-old male.
A, B. Axial thin-section CT scan at the level of lung bases (lung window) (A) and (B), mediastinal window show two rounded opacities of 
different sizes in the lateral segment of the middle lobe and in the superior segment of the right lower lobe (black arrows in A; white arrows in B); 
largest nodule shows central cavitation with thick walls and irregular inner margins (blackarrowhead in A).
A B
Fig. 15. Granulomatosis with polyangiitis (reversed halo sign).
A, B. Axial (A) and coronal (B) thin-section CT shows bilateral rounded opacities of different sizes with a central hypodense zone surrounded by 
a ring of consolidation (reversed halo sign) (arrows). C. Medium power magnification of lung demonstrates necrotizing vasculitis evidenced by an 





usually in the fourth decade, may persist for many years, 
and is characterized by the occurrence of asthma, allergic 
rhinitis, and sinusitis; 2) eosinophilic phase, with marked 
peripheral eosinophilia and eosinophilic organ infiltrations, 
especially in the lungs, heart, and gastrointestinal system; 
3) vasculitic phase, with consequences of a necrotizing 
vasculitis generally associated with vascular or extravascular 
granulomatosis and constitutional symptoms, such as fever, 
malaise, and weight loss [151,155].
There is a spectrum of histopathologic findings of EGPA 
in the lung. The combination of eosinophilic pneumonia, 
necrotizing vasculitis, and granulomatous inflammation is 
considered diagnostic but is infrequently present [156]. 
Alveolar spaces are often involved in eosinophils, fibrin, 
organizing fibrosis, and reactive type II pneumocytes. In 
the absence of vasculitis (clinical or histological), it may be 
difficult to distinguish between EGPA and other eosinophilic 
disorders.
The most common radiographic findings consist of bilateral 
multifocal consolidation, patchy nonsegmental consolidation, 
and multiple nodules. Less common intrathoracic findings 
include mediastinal or hilar lymphadenopathy and pleural or 
pericardial effusion [138,157]. 
HRCT appearances largely reflect the eosinophilic 
infiltrate, including migrating patchy infiltrates with 
a predominantly peripheral distribution, ground-glass 
opacities, areas of airspace consolidation, centrilobular 
nodules, and airway abnormalities attributable to asthma 
[158]. These findings reflect the presence of eosinophilic 
infiltration of the airspaces, interstitium, airways, and 
interstitial edema [159]. Interlobular septal thickening 
may be seen as a result of interstitial edema secondary 
to cardiac involvement [159]. Histologically, airspace 
consolidation is due to eosinophils, fibrin, foci of organizing 
pneumonia, and reactive type II pneumocytes. Up to 25% 
of patients have few or no imaging abnormalities, and 
imaging is often of little help in arriving at this somewhat 
elusive diagnosis (Fig. 16) [160].
Collagen Vascular Diseases
Rheumatoid Lung Nodules
Rheumatoid pulmonary nodules are an uncommon but 
well-described extra-articular manifestation of rheumatoid 
disease, occurring most often in cigarette smokers with 
clinical and radiographic evidence of rheumatoid arthritis 
[161,162]. The incidence in the lung is approximately 
30–40% of cases [163]. Usually, they are multiple and 
pleural based, and may vary in size from a few millimeters 
to 7 cm. They may resolve spontaneously, wax and wane in 
Fig. 16. Eosinophilic granulomatosis with polyangiitis in a 23-year-old male with severe asthma.
A. Axial thin-section CT scan (lung window) at the level of the carina shows an ill-defined nodule surrounded by a halo of ground-glass 
attenuation (arrow) in the right upper lobe. Note bilateral thickening of bronchial walls (arrowheads). B. Axial thin-section CT at the level of 
lung bases shows bilateral thickening of bronchioles (arrows), mucous plugging and basilar-predominant centrilobular nodules of varying sizes 
(arrowheads). C. Lung biopsy was done through video-assisted thoracic surgery. Low-power magnification shows airway destruction (arrows) with 
submucosal infiltration and luminal filling with lymphocytes and eosinophils (arrowheads) (hematoxylin and eosin stain, X 400). 
A B C
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concert with the disease activity, or may antedate arthritis 
[164]. Nodules are typically asymptomatic and require no 
treatment unless they become quite large, infected, or 
cavitated. Approximately 50% of rheumatoid pulmonary 
nodules will cavitate and can sometimes be associated 
with pleural effusion, pneumothorax, or pyopneumothorax 
[165,166]. The majority of spontaneous pneumothoraces 
related to rheumatoid arthritis are associated with 
subpleural necrobiotic pulmonary nodules [167].
Histologically, necrobiosis with and palisading epithelioid 
histiocytes is a typical feature. The area of central necrosis 
contains necrotizing endothelial cells and histiocytes. The 
outer area tends to show granulation tissue with chronic 
inflammatory cells and significant stromal fibrosis. Focal 
vasculitis and occasional giant cells can also be found [168]. 
Overall, this represents an immune-mediated granulomatous 
process and shows granulation tissue with chronic 
inflammatory cells and significant stromal fibrosis [169].
Fig. 17. Rheumatoid nodules.
A, B. Axial (A) and sagittal thin-section CT (B) images show numerous subpleural pulmonary necrotic (arrows) and solid (arrowheads) necrobiotic 
pulmonary nodules.
A B
Fig. 18. Rheumatoid nodule.
A. Coronal reformatted contrast-enhanced CT shows a peripheral right upper lobe cavitary mass (arrow). B. Surgical gross specimen shows an ill-
defined cavitary mass (black arrows) containing necrotic tissue (white arrows). C. Low-power scanning magnification of lung demonstrates a 
necrotizing granuloma with a central zone of necrosis (white arrow) surrounded by a rim of palisading histiocytes (black arrows). The dark blue 





CT features more commonly associated with rheumatoid 
lung nodules consist of multiplicity, smooth border, 
cavitation, satellite nodules, pleural contact, and a 
subpleural rind of soft tissue (Figs. 17, 18) [170].
CONCLUSION
The diagnosis of non-infectious pulmonary granulomatosis 
is difficult because of the variable clinical manifestations 
and radiologic features. The anatomic distribution of the 
lesions and radiologic details in conjunction with patients’ 
clinical history is imperative for narrowing the differential 
diagnosis in order to facilitate proper management.
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